A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors

Trial ID # NCT02734004; MEDIOLA
Phase I/II
Drug Class Angiogenesis Inhibitors: VEGF
Drug Name Bevacizumab
Alternate Drug Names immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin
Drugs in Trial Bevacizumab, Durvalumab, Olaparib
Eligible Participant

Advanced solid tumors with no prior PARP inhibitor or PD-1/PD-L1 inhibitor

Patients Enrolled

288 [ovarian: 31 Pt-S non-gBRCA MUT; median 1 prior therapy (1-2)]

Therapy Setting


Study Design

Open-Label, Non-randomized


CBR, ORR, DCR, DoR, PFS, OS, evaluated per RECIST




Bev+Ola+Durnon-gBRCA MUT (n=31):
ORR: 87%
CBR: 74%
DCR (56 weeks): 38.7%
DoR: 11 months
PFS: 14.7 months
OS: 31.9 months

Clinically Significant Adverse Events

Serious AE: none
Grade 3-4 AE: anemia (17.6%), elevated lipase (11.8%)


Promising activity of bevacizumab+olaparib+durvalumab in non-gBRCA MUT patients regardless of LOH score and mutation status of common DDR genes


Drew Y et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Annals Oncol (2020) 31 (suppl_4): abstract 814MO

MEDIOLA Examines Triplet Therapy in Ovarian Cancer — New cohort adds bevacizumab to olaparib /durvalumab combo, MedPage today 10/7/2020 

Bannerjee S et al. Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer. ESMO (2022) abstract 529MO

Drew Y et al. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clin Cancer Res (2024) 30(1):50-62

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.